These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15283038)

  • 1. [Is there an indication for the association of betablockers and angiotensin II receptor antagonists in cardiac failure?].
    Jondeau G; Milleron O; Morisson-Castagnet JF
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):641-6. PubMed ID: 15283038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 4. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P
    Orv Hetil; 2005 May; 146(18):827-31. PubMed ID: 15926627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ACE inhibitors, beta blockers, AT-1 antagonists in heart failure. Right dosage and combination].
    Fliri M
    MMW Fortschr Med; 2002 Nov; 144(48):38-43. PubMed ID: 12532542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of chronic heart failure: current views].
    Komajda M
    Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):603-6. PubMed ID: 7487309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
    McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
    J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM; Kamper AL
    Ugeskr Laeger; 2003 Oct; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2005 Jan; 125(1):38-40. PubMed ID: 15643463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
    Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR; Krum H
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.